company background image
WOCK

Wockhardt NSEI:WOCKPHARMA Stock Report

Last Price

₹212.65

Market Cap

₹30.6b

7D

-3.6%

1Y

-59.8%

Updated

28 Jun, 2022

Data

Company Financials
WOCKPHARMA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

WOCKPHARMA Stock Overview

Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, Europe, and internationally.

Wockhardt Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Wockhardt
Historical stock prices
Current Share Price₹212.65
52 Week High₹592.00
52 Week Low₹210.05
Beta1.5
1 Month Change-20.59%
3 Month Change-22.65%
1 Year Change-59.78%
3 Year Change-42.57%
5 Year Change-64.45%
Change since IPO-21.19%

Recent News & Updates

Jun 23
Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?

Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Shareholder Returns

WOCKPHARMAIN PharmaceuticalsIN Market
7D-3.6%1.3%1.8%
1Y-59.8%-16.3%0.6%

Return vs Industry: WOCKPHARMA underperformed the Indian Pharmaceuticals industry which returned -15.9% over the past year.

Return vs Market: WOCKPHARMA underperformed the Indian Market which returned -0% over the past year.

Price Volatility

Is WOCKPHARMA's price volatile compared to industry and market?
WOCKPHARMA volatility
WOCKPHARMA Average Weekly Movement7.3%
Pharmaceuticals Industry Average Movement6.9%
Market Average Movement7.0%
10% most volatile stocks in IN Market9.9%
10% least volatile stocks in IN Market4.5%

Stable Share Price: WOCKPHARMA is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: WOCKPHARMA's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19995,000Murtaza Khorakiwalahttps://www.wockhardt.com

Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, Europe, and internationally. The company offers generic products comprising injectables, such as cephalosporins and non-cephalosporins; molecules; and value-added generics. Its biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine.

Wockhardt Fundamentals Summary

How do Wockhardt's earnings and revenue compare to its market cap?
WOCKPHARMA fundamental statistics
Market Cap₹30.63b
Earnings (TTM)-₹2.44b
Revenue (TTM)₹32.30b

0.9x

P/S Ratio

-12.6x

P/E Ratio

Is WOCKPHARMA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
WOCKPHARMA income statement (TTM)
Revenue₹32.30b
Cost of Revenue₹12.67b
Gross Profit₹19.63b
Other Expenses₹22.07b
Earnings-₹2.44b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-16.94
Gross Margin60.77%
Net Profit Margin-7.55%
Debt/Equity Ratio44.3%

How did WOCKPHARMA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is WOCKPHARMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for WOCKPHARMA?

Other financial metrics that can be useful for relative valuation.

WOCKPHARMA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.6x
Enterprise Value/EBITDA17.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does WOCKPHARMA's PS Ratio compare to its peers?

WOCKPHARMA PS Ratio vs Peers
The above table shows the PS ratio for WOCKPHARMA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average11.8x
STAR Strides Pharma Science
1x18.2%₹31.5b
524735 Hikal
1.6x12.3%₹31.5b
530549 Shilpa Medicare
3x10.3%₹34.1b
SPARC Sun Pharma Advanced Research
41.6xn/a₹57.1b
WOCKPHARMA Wockhardt
0.9xn/a₹30.6b

Price-To-Sales vs Peers: WOCKPHARMA is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (11.8x).


Price to Earnings Ratio vs Industry

How does WOCKPHARMA's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

Price-To-Sales vs Industry: WOCKPHARMA is good value based on its Price-To-Sales Ratio (0.9x) compared to the Indian Pharmaceuticals industry average (1.7x)


Price to Sales Ratio vs Fair Ratio

What is WOCKPHARMA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

WOCKPHARMA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate WOCKPHARMA's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of WOCKPHARMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: WOCKPHARMA (₹212.65) is trading above our estimate of fair value (₹145.01)

Significantly Below Fair Value: WOCKPHARMA is trading above our estimate of fair value.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate WOCKPHARMA's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Wockhardt forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


22.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wockhardt has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Wockhardt's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Wockhardt competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Wockhardt performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


28.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: WOCKPHARMA is currently unprofitable.

Growing Profit Margin: WOCKPHARMA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: WOCKPHARMA is unprofitable, but has reduced losses over the past 5 years at a rate of 28.2% per year.

Accelerating Growth: Unable to compare WOCKPHARMA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: WOCKPHARMA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9%).


Return on Equity

High ROE: WOCKPHARMA has a negative Return on Equity (-6.64%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Wockhardt's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: WOCKPHARMA's short term assets (₹25.9B) do not cover its short term liabilities (₹32.1B).

Long Term Liabilities: WOCKPHARMA's short term assets (₹25.9B) exceed its long term liabilities (₹8.3B).


Debt to Equity History and Analysis

Debt Level: WOCKPHARMA's net debt to equity ratio (34.4%) is considered satisfactory.

Reducing Debt: WOCKPHARMA's debt to equity ratio has reduced from 111.8% to 44.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable WOCKPHARMA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: WOCKPHARMA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 32.9% per year.


Discover healthy companies

Dividend

What is Wockhardt current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate WOCKPHARMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate WOCKPHARMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if WOCKPHARMA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if WOCKPHARMA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: WOCKPHARMA is not paying a notable dividend for the Indian market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as WOCKPHARMA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

10.8yrs

Average management tenure


CEO

Murtaza Khorakiwala (48 yo)

13.17yrs

Tenure

₹24,000,000

Compensation

Dr. Murtaza Habil Khorakiwala serves as the Managing Director of Wockhardt Ltd. since April 2009 and has been its Executive Director since March 31, 2009. Dr. Khorakiwala serves as a Director of Khorakiwal...


CEO Compensation Analysis

Compensation vs Market: Murtaza's total compensation ($USD306.01K) is about average for companies of similar size in the Indian market ($USD259.68K).

Compensation vs Earnings: Murtaza's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: WOCKPHARMA's management team is seasoned and experienced (10.8 years average tenure).


Board Members

Experienced Board: WOCKPHARMA's board of directors are considered experienced (9.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30%.


Top Shareholders

Company Information

Wockhardt Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Wockhardt Limited
  • Ticker: WOCKPHARMA
  • Exchange: NSEI
  • Founded: 1999
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹30.633b
  • Shares outstanding: 144.05m
  • Website: https://www.wockhardt.com

Number of Employees


Location

  • Wockhardt Limited
  • Wockhardt Towers
  • Bandra Kurla Complex
  • Mumbai
  • Maharashtra
  • 400051
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/28 00:00
End of Day Share Price2022/06/28 00:00
Earnings2022/03/31
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.